Menu
Synergy in Action

2010 Autumn Conference

13 – 14 October, 2010   //   Baltimore, Maryland, USA

Poster Awardees:

Randomization Strategies for Clustered Clinical Syndromes: Effects on Statistical Power
B Lebowitz, Y Wang, N Duan, CF Reynolds III, NM Simon, S Zisook, MK Shear
Reconsidering the Criterion for Excluding Comorbid Substance Use Disorders from Clinical Trials for the Treatment of Depression
L Davis
Methodological Challenges of Demonstrating Cognitive Improvements with Broad Spectrum Agents: A Novel Approach
Y Geffen, M Davidson, M Hufford, RM Gendreau, S Rao, R.Zablocki, J Kranzler

Day 1 (13 October 2010)

President’s Welcome L Alphs
slides slides
video
S1: MATRICS Update and Beyond
Chairs:
S Marder
M Egan
Introduction S Marder
slides slides
video
The MATRICS Approach to Measuring Cognition: Foundational Issues and Critical Decisions M Green
slides slides
Real-World Application of the MATRICS Consensus Cognitive Battery (MCCB) in Multisite Clinical Trials R Keefe
slides slides
video
Assessment of Functional Outcomes D Velligan
slides slides
video
Challenges in Drug Development for Cognitive Impairment Associated with Schizophrenia M Egan*
Cognition in Schizophrenia: New Directions in Clinical Trials at NIMH B Cuthbert
slides slides
Bridging the Gaps Between Animal Models, Human Neuroscience and Schizophrenia Clinical Trials: Rational Enhancement of Signal Detection J Sweeney
slides slides
Cognitive Remediation as a Platform for Clinical Trials of Cognitive Enhancing Drugs in Schizophrenia A Reichenberg
slides slides
Cognitive Assessment for Schizophrenia Clinical Trials in the Post-MATRICS Era R Bilder
slides slides
Standardized Approach to Clinical Trials: Risks, Benefits, and a Working Model S Koslow
slides slides
Exemplar Applications and Results From BRAINnet: What Are The Implications for Understanding, Modeling, Diagnosing and Treating Brain Disorders? S Silverstein
slides slides
Regulatory Perspective MATRICS and Beyond: US Perspective T Laughren
video
Regulatory Perspective MATRICS and Beyond: European Perspective K Broich
slides slides
video
Panel Discussion Chair:
M Egan
video
Panelists:
K Broich
T Laughren
R Keefe

video
Summary S Marder
video
Poster Session View All Poster Abstracts

Day 2 (14 October 2010)

S2: Concurrent Workshops  
  Sources And Management Of Placebo Effects In CNS Clinical Trials A Kalali
L Ereshefsky
slides slides (summary)
  Methodological Issues for Studying Negative Symptoms of Schizophrenia S Marder
D Daniel

video
  Health Information Technology and Electronic Medical Records: What Are the Scientific and Policy Priorities for the Field of CNS Clinical Research? J Davis
R Ferziger
  Questionable Data: Recognition and Resolution G Sachs
J Severe

slides slides (Colton)
slides slides (summary)
video
  Mitochondrial Systems as Targets for Development of Novel Pharmacological Interventions for CNS Disorders
Session Summary
C Bowden
A Nierenberg

slides slides (summary)
  Suicidality Assessment in Clinical Trials: Methodological and Technical Challenges A Butler
M Stewart

slides slide (Mathis)
slides slides (summary)
Session 3: DSM-5: Implications for Clinical Trials Chairs:
N Schooler
R Hirschfeld
Introduction N Schooler
video
Implications of DSM-5 Mood Disorders for Future Treatment Efficacy Trials J Fawcett
slides
slides
video
Schizophrenia and Psychotic Disorders in DSM-5 J Bustillo
slides slides
Regulatory Perspectives from FDA and EMEA M Mathis
slides slides
K Broich
slides slides
Public Perspective J McNulty
video
General Discussion R Hirschfeld
Meeting Adjourns  
* Materials have not been released.